Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gene regulation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    63 result(s) found for: Gene regulation. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2009-011097-15 Sponsor Protocol Number: OLA_ZIPRA Start Date*: 2009-08-25
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
    Full Title: Effect of atypical antipsychotics on gene expression in soft tissues of healthy subjects. A placebo controlled randomised pilot study.
    Medical condition: The study will be conducted in 42 healthy volunteers
    Disease:
    Population Age: Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002069-30 Sponsor Protocol Number: 13069 Start Date*: 2008-12-05
    Sponsor Name:Bayer Vital GmbH
    Full Title: A randomized, double-blind, single centre, placebo-controlled pilot study to assess on a molecular level the influence of a 5 % dexpanthenol ointment in subjects with previously injured skin by inv...
    Medical condition: Biopsy wounds on healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005266-34 Sponsor Protocol Number: UX701-CL301 Start Date*: 2022-02-11
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Seamless, Adaptive, Safety, Dose-finding, and Phase 3 Clinical Study of UX701 AAV-mediated Gene Transfer for the Treatment of Wilson Dis...
    Medical condition: Wilson disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003814-14 Sponsor Protocol Number: ML19498 Start Date*: 2006-03-13
    Sponsor Name:Unidad Integral de Investigación en Oncología, S.L.
    Full Title: Pharmacodynamic study of Erlotinib (Tarceva) in patients with mestastatic or locally advanced Epidermoid carcinoma of the head and neck
    Medical condition: Mestastatic or locally advanced Epidermoid carcinoma of the head and neck
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003938-41 Sponsor Protocol Number: IMP 28364 Start Date*: 2007-09-25
    Sponsor Name:Merck Lipha Santé SAS
    Full Title: Open label pilot study on gene expression profiling of the endometrial tissue in patients undergoing Assisted Reproductive Technology (ART: only IVF) with GONAL-f.
    Medical condition: This study will be conducted in infertile women justifying ART (Assisted Reproductive Technology) treatment (only IVF - In Vitro Fecondation)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056204 In vitro fertilisation LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002095-40 Sponsor Protocol Number: B2151005 Start Date*: 2014-06-12
    Sponsor Name:Pfizer Inc.,235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED PHASE 2 STUDY OF PF-05212384 PLUS IRINOTECAN VERSUS CETUXIMAB PLUS IRINOTECAN IN PATIENTS WITH KRAS AND NRAS WILD TYPE METASTATIC COLORECTAL CANCER
    Medical condition: Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10018065 - General disorders and administration site conditions 10069755 K-ras gene mutation PT
    17.0 10018065 - General disorders and administration site conditions 10071972 N-ras gene mutation PT
    17.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-002096-18 Sponsor Protocol Number: B2151007 Start Date*: 2014-08-13
    Sponsor Name:Pfizer Inc.,235 East 42nd Street, New York, NY 10017
    Full Title: AN OPEN-LABEL, MULTI-CENTER, RANDOMIZED PHASE 1B/2 STUDY OF PF05212384 PLUS 5-FLUOROURACIL-LEUCOVORIN-IRINOTECAN (FOLFIRI) VERSUS BEVACIZUMAB PLUS FOLFIRI IN METASTATIC COLORECTAL CANCER
    Medical condition: Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-005013-11 Sponsor Protocol Number: D2452L00007 Start Date*: 2005-02-01
    Sponsor Name:Umeå University Hospital
    Full Title: A 36 wk three-center double-blind randomized three-way cross-over trial comparing metabolic effects of candesartan, hydrochlorothiazide and placebo. The MEDICA study Mechanisms for the diabetes-p...
    Medical condition: The "metabolic syndrome" is a cluster of metabolic and cardiovascular risk factors. Insulin resistance appears to be a central disease mechanism and hypertension is another important component. A t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003633-33 Sponsor Protocol Number: MAXEPA01 Start Date*: 2011-09-29
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: The effect of purified fish oils on glucose regulation in Congenital Hyperinsulinism of Infancy (CHI)
    Medical condition: Congenital hyperinsulinism
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10062329 Congenital endocrine anomaly PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000876-27 Sponsor Protocol Number: ATX-MTM-002 Start Date*: 2017-12-06
    Sponsor Name:Audentes Therapeutics Inc.
    Full Title: ASPIRO: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-L...
    Medical condition: X-linked Myotubular Myopathy (XLMTM)
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2016-005112-17 Sponsor Protocol Number: IRFMN-BRC-7103 Start Date*: 2017-07-11
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Multicenter, randomized, phase II study of neoadjuvant chemotherapy associated or not with zoledronate and atorvastatin in triple negative breast cancers - YAPPETIZER Study
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002087-12 Sponsor Protocol Number: BN40703 Start Date*: 2018-12-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10079419 Spinal muscular atrophy pre-symptomatic LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) PL (Trial now transitioned) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004130-15 Sponsor Protocol Number: CRC-AGA-M-A-11 Start Date*: 2014-06-03
    Sponsor Name:Charité-Universitätsmedizin Berlin, Department of Dermatology, Clinical Research Center for Hair and Skin Science
    Full Title: Investigator-initiated clinical research trial on the effects of 5% Minoxidil topical foam on gene expression, hair growth and scalp microenvironment in men with androgenetic alopecia
    Medical condition: Androgenetic Alopecia Hamilton-Norwood IIIv-IV male patients
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10068168 Androgenetic alopecia PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000942-77 Sponsor Protocol Number: EFC14028 Start Date*: 2016-07-15
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase ...
    Medical condition: Pompe disease (acid alpha-glucosidase deficiency)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036143 Pompe's disease LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Prematurely Ended) SE (Prematurely Ended) NL (Completed) ES (Completed) CZ (Completed) DE (Completed) BE (Completed) AT (Completed) PL (Completed) IT (Completed) PT (Completed) BG (Completed) HU (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-010516-15 Sponsor Protocol Number: 3227K1-2000-WW Start Date*: 2009-08-14
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: Randomized, Parallel, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of SBI-087 in Seropositive Subjects With Active Rheumatoid Arthritis on a Stable Background of Metho...
    Medical condition: Rheumatoid arthritis (seropositive)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040107 Seropositive rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2022-003879-42 Sponsor Protocol Number: 2021/ABM/03/00006 Start Date*: 2023-04-12
    Sponsor Name:Medical Univeristy of Bialystok
    Full Title: A randomized, controlled, double-blind clinical trial evaluating the effect of METformin treatment on endometrial function in women diagnosed with Idiopathic Infertility
    Medical condition: Potential causes of idiopathic infertility include in particular: abnormal function of the endometrium, including implantation disorders and immunological abnormalities, genetic abnormalities and t...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10016471 Fertility and fertilisation interventions female HLT
    20.0 10038604 - Reproductive system and breast disorders 10021928 Infertility female PT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012676-27 Sponsor Protocol Number: FemExp-I Start Date*: 2010-01-24
    Sponsor Name:Wallenberg laboratory
    Full Title: Femoral-Express-I
    Medical condition: Peripheral artery disease. Patients due for by-pass surgery of lower extremity arteries.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10034638 Peripheral vascular disorders NEC HLT
    12.0 10003611 Atherosclerosis of arteries of the extremities, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001494-15 Sponsor Protocol Number: 311135 Start Date*: 2008-07-08
    Sponsor Name:Bayer Schering Pharma
    Full Title: Phase I/II Study of Sagopilone in combination with carboplatin and bevacizumab in the first-line treatment of patients with stage IIIB/IV, non-squamous NSCLC.
    Medical condition: Treatment of patients with non-squamous NSCLC, Stage IIIB (with malignant pleural effusion) or Stage IV disease with no prior systemic treatment.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004823-21 Sponsor Protocol Number: PBI-4050-CT-9-10 Start Date*: 2017-10-25
    Sponsor Name:Prometic Biosciences Inc.
    Full Title: An Open-Label Rollover Study of PBI-4050 in Subjects with Alström Syndrome
    Medical condition: Alström Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10068814 Alstrom syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001484-27 Sponsor Protocol Number: NL67672.091.18 Start Date*: 2023-01-24
    Sponsor Name:radboudumc
    Full Title: B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic Sclerosis Tissues Analysis 2
    Medical condition: Systemic Sclerosis Sjögren's Syndrome Cutaneous Lupus Erythematodus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 23:49:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA